Por favor, use este identificador para citar o enlazar este ítem:
https://observatoriovacunascovid19.unam.mx/jspui/jspui/handle/123456789/7
Título : | SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice |
Autor : | Tian, Jing-Hui Patel, Nita Haupt, Robert Zhou, Haixia Weston, Stuart Hammond, Holly Logue, James Portnoff, Alyse D. Norton, James Guebre-Xabier, Mimi Zhou, Bin Jacobson, Kelsey Maciejewski, Sonia Khatoon, Rafia Wisniewska, Malgorzata Moffitt, Will Kluepfel-Stahl, Stefanie Ekechukwu, Betty Papin, James Boddapati, Sarathi Wong, C. Jason Piedra, Pedro A. Frieman, Matthew B. Massare, Michael J. Fries, Louis Lövgren Bengtsson, Karin Stertman, Linda Ellingsworth, Larry Glenn, Gregory Smith, Gale |
Palabras clave : | vacunas vaccines NVX-CoV2373 Novavax inmunogenicidad seguridad estudios preclínicos vacunas de subunidades |
Fecha de publicación : | 14-Jan-2021 |
Editorial : | Springer Nature Limited |
Citación : | Nature Communications 2021;12:372. |
Resumen : | The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2. Here, we report the development of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) from the full-length spike (S) protein that is stable in the prefusion conformation. NVX-CoV2373 S form 27.2-nm nanoparticles that are thermostable and bind with high affinity to the human angiotensin-converting enzyme 2 (hACE2) receptor. In mice, low-dose NVX-CoV2373 with saponin-based Matrix-M adjuvant elicit high titer anti-S IgG that blocks hACE2 receptor binding, neutralize virus, and protects against SARS-CoV-2 challenge with no evidence of vaccine-associated enhanced respiratory disease. NVX-CoV2373 also elicits multifunctional CD4+ and CD8+ T cells, CD4+ follicular helper T cells (Tfh), and antigen-specific germinal center (GC) B cells in the spleen. In baboons, low-dose levels of NVX-CoV2373 with Matrix-M was also highly immunogenic and elicited high titer anti-S antibodies and functional antibodies that block S-protein binding to hACE2 and neutralize virus infection and antigen-specific T cells. These results support the ongoing phase 1/2 clinical evaluation of the safety and immunogenicity of NVX-CoV2373 with Matrix-M (NCT04368988). |
URI : | https://www.nature.com/articles/s41467-020-20653-8 https://observatoriovacunascovid19.unam.mx/jspui/jspui/handle/123456789/7 |
Aparece en las colecciones: | Artículos científicos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Portada 2.png | 174.8 kB | image/png | Visualizar/Abrir |
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.